Amphista Therapeutics Limited

At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches, addressing limitations associated with the use of a narrow range of protein degrading mechanisms. Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cells degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein...

Targeted protein degradation ,biology,chemistry,drug discovery,and development

Amphista therapeutics limited operates in the Biotechnology research industry.

Amphista therapeutics limited's revenue is 11m - 100m

Amphista therapeutics limited has 51 - 200 employees.